Last reviewed · How we verify
Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
Details
| Lead sponsor | Seagen Inc. |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 160 |
| Start date | 2000-10 |
| Completion | 2003-07 |
Conditions
- Prostatic Neoplasms
Interventions
- SGN-15 (cBR96-doxorubicin immunoconjugate)
- Taxotere (docetaxel)
Countries
United States